Goldman Sachs stock edges higher before CPI and a packed week of bank earnings

Goldman Sachs stock edges higher before CPI and a packed week of bank earnings

NEW YORK, January 9, 2026, 20:00 EST — Market closed.

Shares of The Goldman Sachs Group Inc (GS) closed Friday up roughly 0.4%, finishing at $938.98, gaining $4.15 from Thursday’s close. The stock fluctuated between $932.84 and $946.14 during the session, with around 1.1 million shares changing hands.

Goldman now faces a hectic period as major U.S. banks prepare to kick off fourth-quarter earnings. Investors will be watching closely for early signals on the economy and deal activity. “The banks are going to be telling you something that is going to be pretty important because they’re on the front lines,” said Jack Janasiewicz, portfolio manager at Natixis Investment Managers Solutions.

Tuesday delivers December’s consumer price index, a crucial inflation gauge that could shift forecasts for Federal Reserve rate cuts. The Fed is set to meet next on Jan. 27-28. (Bureau of Labor Statistics)

U.S. stocks wrapped up the week strong, with the S&P 500 hitting a new peak at 6,966.28, up 0.65%. December’s jobs report revealed hiring slowed more than anticipated, even as unemployment slipped to 4.4%. One strategist noted investors are “getting granular” in their stock selections.

In deal news, Bloomberg reports CK Hutchison has tapped Goldman and UBS to lead a planned IPO for A.S. Watson, aiming to raise $2 billion or more. The listing is expected to be dual, covering both Hong Kong and London. This move adds another item for investors tracking whether equity issuance is truly picking up. (Reuters)

Goldman closes the week roughly 2.4% shy of its 52-week peak at $961.69, while the 52-week trough stands at $439.38. Analysts note resistance near $945.85 and support around $932.41—essentially zones where selling or buying pressure tends to kick in.

Goldman plans to release its fourth-quarter earnings around 7:30 a.m. ET on Jan. 15, with a conference call set for 9:30 a.m. Traders will focus on market trading results, any rise in investment-banking fees, and cost trends as the firm heads into 2026.

But the path ahead is far from certain. A stronger inflation report or new tariff concerns could shake up rate forecasts and weaken demand for bank shares, despite any renewed buzz about deals. (Reuters)

Up next: the December 2025 CPI data, due out at 8:30 a.m. ET on Jan. 13. JPMorgan is set to release earnings before the open that day, with Bank of America following on Jan. 14. Morgan Stanley and Goldman Sachs will report on Jan. 15. (Bureau of Labor Statistics)

Stock Market Today

  • Three safe dividend stocks to own in any market: Fortis, Granite REIT, and Chartwell
    January 10, 2026, 8:48 PM EST. Three dividend stocks are built to endure market swings: Fortis, Granite Real Estate Investment Trust, and Chartwell Retirement Residences. Fortis has a 52-year dividend-growth run, a beta of about 0.4, and total returns near 9.5% including dividends. It yields roughly 3.5% and targets mid-single-digit earnings growth as rate-base expansion continues. Granit REIT, Canada's largest industrial REIT by market cap, owns logistics and warehousing assets across North America and Europe. It offers a 4.3% monthly distribution, has raised its payout for 15 straight years, and benefits from a solid balance sheet and high tenant quality, with occupancy above 97%. Chartwell Retirement Residences, Canada's largest seniors' operator, rebounded after the pandemic. Occupancy rose from about 86% in 2023 to 95% end-2025, cash flow per unit improved, and the stock has rallied roughly 161% since 2023, underpinned by aging demographics.
Credo Technology stock jumps on Needham “Top Pick” call as CEO sale filing hits tape
Previous Story

Credo Technology stock jumps on Needham “Top Pick” call as CEO sale filing hits tape

Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus
Next Story

Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Go toTop